search
Back to results

Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan

Primary Purpose

Type1diabetes, Fasting, Insulin

Status
Completed
Phase
Not Applicable
Locations
Saudi Arabia
Study Type
Interventional
Intervention
Timing of taking insulin
Sponsored by
King Abdullah International Medical Research Center
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Type1diabetes focused on measuring Type1 Diabetes, Fasting, Insulin Glargine, Ramadan, Hypoglycemia

Eligibility Criteria

14 Years - undefined (Child, Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. DM type 1
  2. Age > 14 years
  3. Diagnosis of type 1 DM of more than 6 months.
  4. Committed to do SMBG

Exclusion Criteria:

  1. Renal and hepatic impairment
  2. Adrenal insufficiency
  3. Pregnancy
  4. Alcohol consumption
  5. Any diagnosed psychiatric disease

Sites / Locations

  • KingAbullahIMRC

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Early Glargine

Late Glargine

Arm Description

To take insulin Glargine at 6-7 pm

To take insulin Glargine at 10-12 pm

Outcomes

Primary Outcome Measures

Hypoglycemia incidence
To determine if taking basal insulin Glargine at 6 pm is associated with less rates of hypoglycemia -(we will consider glucose level of 70 mg/dl ( 3.9 mmol/l) and below as the level of hypoglycemia ) - compared to bedtime timing (10-12pm) during fasting Ramadan in patients with T1DM.

Secondary Outcome Measures

Glucose variability
To estimate the difference between the two groups in glucose variability as measured by standard deviation on glucose monitoring
Days fast broken
To estimate the difference between the two groups in number of days they needed to brake their fast
Glycemic control
To assess the difference in glycemic control between the two groups as measured by hbA1c and frucosamine before and after Ramadan
Hyperglycemia
To estimate the difference between the two groups in overnight and daytime rates of hyperglycemia (BG > 250 mg/dl)
Acute diabetes complications
To estimate the difference between the two groups in rate of severe hyperglycemia (hypoglycemia associated with need for outside assisstance) and /or presentation to ER with Diabetic Keto-acidosis (DKA)

Full Information

First Posted
April 14, 2020
Last Updated
April 27, 2021
Sponsor
King Abdullah International Medical Research Center
search

1. Study Identification

Unique Protocol Identification Number
NCT04383990
Brief Title
Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan
Official Title
Comparison of Early Versus Late Administration of Insulin Glargine in Patients With type1 Diabetes During Fasting Ramadan
Study Type
Interventional

2. Study Status

Record Verification Date
May 2020
Overall Recruitment Status
Completed
Study Start Date
February 28, 2020 (Actual)
Primary Completion Date
August 31, 2020 (Actual)
Study Completion Date
November 30, 2020 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
King Abdullah International Medical Research Center

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Product Manufactured in and Exported from the U.S.
No
Data Monitoring Committee
No

5. Study Description

Brief Summary
To compare different timing of insulin Glargine administration (early-6 pm versus standard bedtime-10 pm) as part of standard of care in patients with type1 diabetes who wish to fast the month of Ramadan.
Detailed Description
The investigators aim to compare the effectiveness and safety of two management strategies currently used in basal insulin adjustment for treatment of Type1 diabetes (T1DM) during fasting the holy month of Ramadan. Primary Objective: To determine if taking basal insulin Glargine at 6 pm is associated with less rates of hypoglycemia -(we will consider glucose level of 70 mg/dl ( 3.9 mmol/l) and below as the level of hypoglycemia ) - compared to bedtime timing (10-12pm) during fasting Ramadan in patients with T1DM Secondary Objectives: To estimate the difference between the two groups in glucose variability To estimate the difference between the two groups in number of days they needed to brake their fast To assess the difference in glycemic control between the two groups To estimate the difference between the two groups in overnight and daytime hyperglycemia. To estimate the difference between the two groups in rate of severe hyperglycemia and /or DKA It is a multi-center open label randomized study that will take place in the diabetes/Endocrine clinics at National Guards Hospitals in four cities (Jeddah, Riyadh, Alhasa, and Dammam) Variables to be Assessed: Patient's demographics including (age, gender, type and duration of diabetes), and baseline measurements (weight, height,BMI, …). Rate of Hypoglycemic events (as per SMBG records and CGM) in both groups Number of days fasting was broken in both groups Rate of severe hyperglycemic episodes (BG>250mg/dl) or DKA in both groups Mean blood glucose for the month of Ramadan as calculated from sum of each patient's 7-point blood sugar home measurements in both groups. Mean 24-hour blood glucose as measured by a continuous glucose monitoring devise in both groups. Mean fasting blood glucose for the month period as calculated from patients home blood sugar measurements in both groups. Mean 2-hour post-prandial blood glucose for the as calculated from patients home blood sugar measurements in both groups. Fructosamine and HbA1c level before and after Ramadan in both groups Results of this study will help fill a current gap of knowledge and may also contribute to the development of future guidelines for the management of type1DM during Ramadan.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Type1diabetes, Fasting, Insulin
Keywords
Type1 Diabetes, Fasting, Insulin Glargine, Ramadan, Hypoglycemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Model Description
Open label Randomized
Masking
None (Open Label)
Allocation
Randomized
Enrollment
185 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Early Glargine
Arm Type
Active Comparator
Arm Description
To take insulin Glargine at 6-7 pm
Arm Title
Late Glargine
Arm Type
Active Comparator
Arm Description
To take insulin Glargine at 10-12 pm
Intervention Type
Other
Intervention Name(s)
Timing of taking insulin
Intervention Description
To take insulin Glargine early (6-7pm) or late (bedtime-10-12pm)
Primary Outcome Measure Information:
Title
Hypoglycemia incidence
Description
To determine if taking basal insulin Glargine at 6 pm is associated with less rates of hypoglycemia -(we will consider glucose level of 70 mg/dl ( 3.9 mmol/l) and below as the level of hypoglycemia ) - compared to bedtime timing (10-12pm) during fasting Ramadan in patients with T1DM.
Time Frame
Through study completion, an average of 3 months
Secondary Outcome Measure Information:
Title
Glucose variability
Description
To estimate the difference between the two groups in glucose variability as measured by standard deviation on glucose monitoring
Time Frame
Through study completion, an average of 3 months
Title
Days fast broken
Description
To estimate the difference between the two groups in number of days they needed to brake their fast
Time Frame
Through study completion, an average of 3 months
Title
Glycemic control
Description
To assess the difference in glycemic control between the two groups as measured by hbA1c and frucosamine before and after Ramadan
Time Frame
Through study completion, an average of 3 months
Title
Hyperglycemia
Description
To estimate the difference between the two groups in overnight and daytime rates of hyperglycemia (BG > 250 mg/dl)
Time Frame
Through study completion, an average of 3 months
Title
Acute diabetes complications
Description
To estimate the difference between the two groups in rate of severe hyperglycemia (hypoglycemia associated with need for outside assisstance) and /or presentation to ER with Diabetic Keto-acidosis (DKA)
Time Frame
Through study completion, an average of 3 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
14 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: DM type 1 Age > 14 years Diagnosis of type 1 DM of more than 6 months. Committed to do SMBG Exclusion Criteria: Renal and hepatic impairment Adrenal insufficiency Pregnancy Alcohol consumption Any diagnosed psychiatric disease
Facility Information:
Facility Name
KingAbullahIMRC
City
Jeddah
Country
Saudi Arabia

12. IPD Sharing Statement

Plan to Share IPD
Undecided

Learn more about this trial

Early Versus Late Administration of Insulin Glargine in T1DM During Fasting Ramadan

We'll reach out to this number within 24 hrs